List view / Grid view




Expanded Phase II trial of savolitinib in NSCLC starts

20 June 2016 | By Victoria White, Digital Content Producer

A Phase II expansion of the ongoing TATTON trial has been initiated to evaluate savolitinib (AZD6094) in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients.